论文部分内容阅读
ＬＭ－ＣＤ４５Ⅱ期临床试验在美国进行坎特伯制药公司和百特保健公司共同开发的领先产品ＬＭ－ＣＤ４５，现已在美国多个中心进行安慰剂对照的Ⅱ期临床试验。该产品用于体外处理供体肾脏，以在移植之前除去器官上的白细胞抗原，试用防止移植排斥反应。该项试验在美国把８...
LM-CD45 Phase II Clinical Trial The LM-CD45, a leading product developed by the Canterbury and Baxter Healthcare companies in the United States, is now a placebo-controlled Phase II clinical trial at multiple centers in the United States. This product is used to treat donor kidneys in vitro to remove organ-derived leukocyte antigens prior to transplantation and to try to prevent transplant rejection. The test in the United States put 8 ...